Please wait a minute...
浙江大学学报（医学版）
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (5): 637-643    DOI: 10.3785/j.issn.1008-9292.2020.08.13
    
Research progress on the role of pentraxin 3 in polycystic ovary syndrome
WU Wei1(),XU Jian1,2,*()
1. Department of Reproductive Endocrinology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
2. Department of Gynecology and Obstetrics, the Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, Zhejiang Province, China
Download: HTML( 6 )   PDF(1070KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Polycystic ovary syndrome (PCOS) is a common endocrine disease of child-bearing period women and one of the main causes of infertility in women. Pentraxin 3 (PTX3) is a multifunctional protein with a series of biological activities. PTX3 participates in the regulation of insulin secretion and glucose metabolism, ovarian cumulus cell function, inflammatory factor activity, androgen metabolism, lipid absorption and transport, and endothelial cell function, thereby improving insulin resistance, promoting follicular development and ovulation, reducing chronic inflammation, inhibiting androgen levels, improving lipid metabolism abnormalities and preventing atherosclerosis and cardiovascular diseases, thus participating in the occurrence of PCOS and its complications. This article reviews the mechanism of PTX3 in PCOS and its complications, trying to provide new ideas and directions for the study of PCOS pathogenesis and its clinical diagnosis and treatment.

Key words： Pentraxin 3      Polycystic ovary syndrome      Insulin resistance      Follicular development      Inflammatory reaction      Lipid metabolism      Androgen      Review     
Received: 03 February 2020      Published: 19 November 2020
CLC:  R711.75  
Corresponding Authors: XU Jian     E-mail: 21718414@zju.edu.cn;xuj@zju.edu.cn
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
WU Wei
XU Jian
Cite this article:

WU Wei,XU Jian. Research progress on the role of pentraxin 3 in polycystic ovary syndrome. J Zhejiang Univ (Med Sci), 2020, 49(5): 637-643.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.08.13     OR     http://www.zjujournals.com/med/Y2020/V49/I5/637


正五聚蛋白3在多囊卵巢综合征中的作用研究进展

多囊卵巢综合征（PCOS）是育龄妇女常见的内分泌疾病，是女性不孕的主要原因之一。正五聚蛋白3（PTX3）是一类多功能蛋白质，具有一系列生物活性作用。PTX3参与调节胰岛素分泌及葡萄糖代谢、卵巢卵丘细胞功能、炎症因子活动、雄激素代谢、脂质吸收转运、内皮细胞功能，进而发挥改善胰岛素抵抗、促进卵泡发育与排卵、减弱慢性炎症反应、抑制雄激素水平、改善脂代谢异常和预防动脉粥样硬化及心血管疾病等作用，参与PCOS及其并发症的发生。本文就PTX3在PCOS及其并发症中的作用机制进行综述，以期为PCOS发病机制的深入研究及临床诊疗提供新的思路与方向。


关键词： 正五聚蛋白3,  多囊卵巢综合征,  胰岛素抵抗,  卵泡发育,  炎症反应,  脂代谢,  雄激素,  综述 
[1]   LI R , ZHANG Q , YANG D et al. Prevalence of polycystic ovary syndrome in women in China:a large community-based study[J]. Hum Reprod, 2013, 28 (9): 2562- 2569
doi: 10.1093/humrep/det262
[2]   NOLAN C J , PRENTKI M . Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes:Time for a conceptual framework shift[J]. Diab Vasc Dis Res, 2019, 16 (2): 118- 127
doi: 10.1177/1479164119827611
[3]   DIAMANTI-KANDARAKIS E , PAPAVASSILIOU A G , KANDARAKIS S A et al. Pathophysiology and types of dyslipidemia in PCOS[J]. Trends Endocrinol Metab, 2007, 18 (7): 280- 285
doi: 10.1016/j.tem.2007.07.004
[4]   SHORAKAE S , TEEDE H , DE COURTEN B et al. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome[J]. Semin Reprod Med, 2015, 33 (4): 257- 269
doi: 10.1055/s-0035-1556568
[5]   COONEY L G , DOKRAS A . Beyond fertility:polycystic ovary syndrome and long-term health[J]. Fertil Steril, 2018, 110 (5): 794- 809
doi: 10.1016/j.fertnstert.2018.08.021
[6]   BONAVITA E , GENTILE S , RUBINO M et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer[J]. Cell, 2015, 160 (4): 700- 714
doi: 10.1016/j.cell.2015.01.004
[7]   BOTTAZZI B , INFORZATO A , MESSA M et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling[J]. J Hepatol, 2016, 64 (6): 1416- 1427
doi: 10.1016/j.jhep.2016.02.029
[8]   CAMAIONI A , KLINGER F G , CAMPAGNOLO L et al. The influence of pentraxin 3 on the ovarian function and its impact on fertility[J]. Front Immunol, 2018, 9 2808
doi: 10.3389/fimmu.2018.02808
[9]   LEALI D , ALESSI P , COLTRINI D et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors[J]. Mol Cancer Ther, 2011, 10 (9): 1600- 1610
doi: 10.1158/1535-7163.MCT-11-0286
[10]   WEISS E P , REEDS D N , EZEKIEL U R et al. Circulating cytokines as determinants of weight loss-induced improvements in insulin sensitivity[J]. Endocrine, 2017, 55 (1): 153- 164
doi: 10.1007/s12020-016-1093-4
[11]   LEE R , AHN H R , SHIN M H et al. Association of plasma pentraxin-3 level with lipid levels and cardiovascular risk factors in people with no history of lipid-lowering medication:the dong-gu study[J]. J Atheroscler Thromb, 2019, 26 (8): 738- 745
doi: 10.5551/jat.47167
[12]   NORATA G D , MARCHESI P , PULAKAZHI VENU V K et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis[J]. Circulation, 2009, 120 (8): 699- 708
doi: 10.1161/CIRCULATIONAHA.108.806547
[13]   DIAMANTI-KANDARAKIS E , DUNAIF A . Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications[J]. Endocr Rev, 2012, 33 (6): 981- 1030
doi: 10.1210/er.2011-1034
[14]   JEANES Y M , REEVES S . Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome:diagnostic and methodological challenges[J]. Nutr Res Rev, 2017, 30 (1): 97- 105
doi: 10.1017/S0954422416000287
[15]   SAHIN F K , SAHIN S B , BALIK G et al. Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity?[J]. Int J Clin Exp Med, 2014, 7 (10): 3512- 3519
[16]   OSORIO-CONLES O, GUITART M, CHACÓN M R, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity[J/OL]. Am J Physiol Endocrinol Metab, 2011, 301(6): E1254-E1261. DOI: 10.1152/ajpendo.00163.2011.
[17]   MIYAKI A , CHOI Y , MAEDA S . Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice[J]. Am J Med Sci, 2014, 347 (3): 228- 233
doi: 10.1097/MAJ.0b013e31828341af
[18]   SLUSHER A L , HUANG C J . Association of pentraxin 3 with insulin resistance and glucose response following maximal aerobic exercise in obese and normal-mass individuals[J]. Can J Physiol Pharmacol, 2016, 94 (7): 734- 738
doi: 10.1139/cjpp-2015-0464
[19]   FRANKS S , STARK J , HARDY K . Follicle dynamics and anovulation in polycystic ovary syndrome[J]. Hum Reprod Update, 2008, 14 (4): 367- 378
doi: 10.1093/humupd/dmn015
[20]   DUMESIC D A , OBERFIELD S E , STENER-VICTORIN E et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome[J]. Endocr Rev, 2015, 36 (5): 487- 525
doi: 10.1210/er.2015-1018
[21]   SALUSTRI A , GARLANDA C , HIRSCH E et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization[J]. Development, 2004, 131 (7): 1577- 1586
doi: 10.1242/dev.01056
[22]   BRIGGS D C , BIRCHENOUGH H L , ALI T et al. Metal ion-dependent heavy chain transfer activity of TSG-6 mediates assembly of the cumulus-oocyte matrix[J]. J Biol Chem, 2015, 290 (48): 28708- 28723
doi: 10.1074/jbc.M115.669838
[23]   TOSI F , DI SARRA D , BONIN C et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome[J]. Eur J Endocrinol, 2014, 170 (3): 401- 409
doi: 10.1530/EJE-13-0761
[24]   CILLO F , BREVINI T A , ANTONINI S et al. Association between human oocyte developmental competence and expression levels of some cumulus genes[J]. Reproduction, 2007, 134 (5): 645- 650
doi: 10.1530/REP-07-0182
[25]   LI X , WANG H , SHENG Y et al. MicroRNA-224 delays oocyte maturation through targeting Ptx3 in cumulus cells[J]. Mech Dev, 2017, 143 20- 25
doi: 10.1016/j.mod.2016.12.004
[26]   ANAGNOSTIS P , TARLATZIS B C , KAUFFMAN R P . Polycystic ovarian syndrome (PCOS):Long-term metabolic consequences[J]. Metabolism, 2018, 86 33- 43
doi: 10.1016/j.metabol.2017.09.016
[27]   DEBAN L , RUSSO R C , SIRONI M et al. Regulation of leukocyte recruitment by the long pentraxin PTX3[J]. Nat Immunol, 2010, 11 (4): 328- 334
doi: 10.1038/ni.1854
[28]   PEREA L , COLL M , SANJURJO L et al. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury[J]. Hepatology, 2017, 66 (3): 953- 968
doi: 10.1002/hep.29215
[29]   RUBINO M, KUNDERFRANCO P, BASSO G, et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer[J/OL]. Oncoimmunology, 2017, 6(7): e1333215. DOI: 10.1080/2162402X.2017.1333215.
[30]   PADMANABHAN V , VEIGA-LOPEZ A , HERKIMER C et al. Developmental programming:prenatal and postnatal androgen antagonist and insulin sensitizer interventions prevent advancement of puberty and improve lh surge dynamics in prenatal testosterone-treated sheep[J]. Endocrinology, 2015, 156 (7): 2678- 2692
doi: 10.1210/en.2015-1235
[31]   RONCA R , ALESSI P , COLTRINI D et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer[J]. J Pathol, 2013, 230 (2): 228- 238
doi: 10.1002/path.4181
[32]   PILTONEN T , PUURUNEN J , HEDBERG P et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women:a randomized study[J]. Hum Reprod, 2012, 27 (10): 3046- 3056
doi: 10.1093/humrep/des225
[33]   GIACOMINI A , MATARAZZO S , PAGANO K et al. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers[J]. Oncotarget, 2015, 6 (15): 13790- 13802
doi: 10.18632/oncotarget.3831
[34]   李宣, 丁卫, 刘嘉茵 et al. 血脂异常对多囊卵巢综合征患者IVF/ICSI妊娠结局的影响[J]. 中华妇产科杂志, 2018, 53 (6): 402- 408
LI Xuan , DING Wei , LIU Jiayin et al. Effects of dyslipidemia on IVF/ICSI pregnancy outcome in patients with polycystic ovary syndrome[J]. Chinese Journal of Obstetrics and Gynecology, 2018, 53 (6): 402- 408
doi: 10.3760/cma.j.issn.0529-567x.2018.06.008
[35]   CASULA M , MONTECUCCO F , BONAVENTURA A et al. Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases[J]. Vascul Pharmacol, 2017, 99 1- 12
doi: 10.1016/j.vph.2017.10.003
[36]   张雨, 胡红琳, 王岩 et al. 初诊多囊卵巢综合征患者空腹血清Pentraxin3的水平变化及意义[J]. 安徽医科大学学报, 2016, 51 (6): 883- 887
ZHANG Yu , HU Honglin , WANG Yan et al. Changes and significance of fasting serum Pentraxin3 levels in patients with newly-diagnosed polycystic ovarian syndrome[J]. Acta Universitatis Medicinalis Anhui, 2016, 51 (6): 883- 887
[37]   WITASP A , CARRERO J J , MICHA?LSSON K et al. Inflammatory biomarker pentraxin 3(PTX3) in relation to obesity, body fat depots and weight loss[J]. Obesity (Silver Spring), 2014, 22 (5): 1373- 1379
doi: 10.1002/oby.20695
[38]   LEKVA T , MICHELSEN A E , BOLLERSLEV J et al. Low circulating pentraxin 3 levels in pregnancy is associated with gestational diabetes and increased apoB/apoA ratio:a 5-year follow-up study[J]. Cardiovasc Diabetol, 2016, 15 23
doi: 10.1186/s12933-016-0345-1
[39]   TRIPATHY P , SAHU A , SAHU M et al. Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2017, 217 18- 22
doi: 10.1016/j.ejogrb.2017.08.011
[40]   HART R , DOHERTY D A . The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage[J]. J Clin Endocrinol Metab, 2015, 100 (3): 911- 919
doi: 10.1210/jc.2014-3886
[41]   O'NEILL C L , GUDURIC-FUCHS J , CHAMBERS S E et al. Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells[J]. Cardiovasc Res, 2016, 112 (3): 677- 688
doi: 10.1093/cvr/cvw209
[42]   WYSKIDA K , FRANIK G , POHL N et al. Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS)[J]. Scand J Clin Lab Invest, 2019, 79 (6): 419- 423
doi: 10.1080/00365513.2019.1637535
[43]   MORISHITA T , UZUI H , NAKANO A et al. Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile:a cross-sectional study in Japanese patients with stable angina pectoris[J]. Heart Vessels, 2018, 33 (11): 1301- 1310
doi: 10.1007/s00380-018-1191-8
[1] LI Mengyao, LIU Pan, KE Yuehai, ZHANG Xue. Research progress on macrophage in radiation induced lung injury[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 623-628.
[2] HAN Xue, JIANG Guojun, SHI Qiaojuan. Effects of antihyperglycemics on endothelial progenitor cells[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 629-636.
[3] DUAN Runping, XU Yesheng, ZHENG Libin, YAO Yufeng. Research progress on etiologic diagnosis of ocular viral diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 644-650.
[4] XU Qinglin,LOU Guodong,WANG Tiantian,ZHANG Lisan. Advances in treatment of narcolepsy[J]. J Zhejiang Univ (Med Sci), 2020, 49(4): 419-424.
[5] JIANG Peiran,WANG Zhiping. Progress on axon regeneration in model organisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(4): 500-507.
[6] CHEN Junyi,YANG Xiang,FANG Xuexian,WANG Fudi,MIN Junxia. The role of ferroptosis in chronic diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 44-57.
[7] ZHAO Weixia,ZOU Wei. Intrinsic and extrinsic mechanisms regulating neuronal dendrite morphogenesis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 90-99.
[8] WANG Yi,LU Yunbi. Poly adenosine diphosphate-ribosylation and neurodegenerative diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 100-106.
[9] YU Qing, XIONG Xiufang, SUN Yi. Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 1-19.
[10] DUAN Lingyan,YIN Xiangju,MENG Hong'en,FANG Xuexian,MIN Junxia,WANG Fudi. Progress on epigenetic regulation of iron homeostasis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 58-70.
[11] LI Ai,ZHANG Tianyuan,GAO Jianqing. Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 20-34.
[12] HUANG Yaoping,YANG Feng,ZHOU Tianhua,XIE Shanshan. Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 35-43.
[13] ZHONG Wen,LOU Yan,QIU Chenyang,LI Donglin,ZHANG Hongkun. Antithrombotic therapy after iliac vein stenting[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 131-136.
[14] XU Yiming,YING Kejing. Research progress on neutrophil extracellular traps in tumor[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 107-112.
[15] LIU Xiaoxiao,GUO Liqiong,LIANG Cheng. Research progress on electroencephalogram characteristics of anti-N-methyl-D-aspartate receptor encephalitis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 118-123.